Article

Deletion and Point Mutations of PTHLH Cause Brachydactyly Type E

Institut für Medizinische Genetik, Charité Universitätsmedizin Berlin, 13353 Berlin, Germany.
The American Journal of Human Genetics (Impact Factor: 10.99). 02/2010; 86(3):434-9. DOI: 10.1016/j.ajhg.2010.01.023
Source: PubMed

ABSTRACT Autosomal-dominant brachydactyly type E (BDE) is a congenital limb malformation characterized by small hands and feet predominantly as a result of shortened metacarpals and metatarsals. In a large pedigree with BDE, short stature, and learning disabilities, we detected a microdeletion of approximately 900 kb encompassing PTHLH, the gene coding for parathyroid hormone related protein (PTHRP). PTHRP is known to regulate the balance between chondrocyte proliferation and the onset of hypertrophic differentiation during endochondral bone development. Inactivation of Pthrp in mice results in short-limbed dwarfism because of premature differentiation of chondrocyte. On the basis of our initial finding, we tested further individuals with BDE and short stature for mutations in PTHLH. We identified two missense (L44P and L60P), a nonstop (X178WextX( *)54), and a nonsense (K120X) mutation. The missense mutation L60P was tested in chicken micromass culture with the replication-competent avian sarcoma leukosis virus retroviral expression system and was shown to result in a loss of function. Thus, loss-of-function mutations in PTHLH cause BDE with short stature.

Download full-text

Full-text

Available from: Olaf Hiort, Jul 03, 2015
0 Followers
 · 
150 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The so-called "enchondromatoses" are skeletal disorders defined by the presence of ectopic cartilaginous tissue within bone tissue. The clinical and radiographic features of the different enchondromatoses are distinct, and grouping them does not reflect a common pathogenesis but simply a similar radiographic appearance and thus the need for a differential diagnosis. Recent advances in the understanding of their molecular and cellular bases confirm the heterogeneous nature of the different enchondromatoses. Some, like Ollier disease, Maffucci disease, metaphyseal chondromatosis with hydroxyglutaric aciduria, and metachondromatosis are produced by a dysregulation of chondrocyte proliferation, while others (such as spondyloenchondrodysplasia or dysspondyloenchondromatosis) are caused by defects in structure or metabolism of cartilage or bone matrix. In other forms (e.g., the dominantly inherited genochondromatoses), the basic defect remains to be determined. The classification, proposed by Spranger and associates in 1978 and tentatively revised twice, was based on the radiographic appearance, the anatomic sites involved, and the mode of inheritance. The new classification proposed here integrates the molecular genetic advances and delineates phenotypic families based on the molecular defects. Reference radiographs are provided to help in the diagnosis of the well-defined forms. In spite of advances, many cases remain difficult to diagnose and classify, implying that more variants remain to be defined at both the clinical and molecular levels.
    American Journal of Medical Genetics Part C Seminars in Medical Genetics 08/2012; 160C(3):154-64. DOI:10.1002/ajmg.c.31331 · 3.54 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: SOX5 encodes a transcription factor involved in the regulation of chondrogenesis and the development of the nervous system. Despite its important developmental roles, SOX5 disruption has yet to be associated with human disease. We report one individual with a reciprocal translocation breakpoint within SOX5, eight individuals with intragenic SOX5 deletions (four are apparently de novo and one inherited from an affected parent), and seven individuals with larger 12p12 deletions encompassing SOX5. Common features in these subjects include prominent speech delay, intellectual disability, behavior abnormalities, and dysmorphic features. The phenotypic impact of the deletions may depend on the location of the deletion and, consequently, which of the three major SOX5 protein isoforms are affected. One intragenic deletion, involving only untranslated exons, was present in a more mildly affected subject, was inherited from a healthy parent and grandparent, and is similar to a deletion found in a control cohort. Therefore, some intragenic SOX5 deletions may have minimal phenotypic effect. Based on the location of the deletions in the subjects compared to the controls, the de novo nature of most of these deletions, and the phenotypic similarities among cases, SOX5 appears to be a dosage-sensitive, developmentally important gene.
    Human Mutation 01/2012; 33(4):728-40. DOI:10.1002/humu.22037 · 5.05 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Durch Deletionen im chromosomalen Bereich 2q37 wird ein klinisches Bild verursacht, das als „Albright-hereditäre-Osteodystrophie(AHO)-ähnliches Syndrom“ bezeichnet wird. Aufgrund der Hauptmerkmale leichte bis mäßig schwere Entwicklungsverzögerung, Verhaltensauffälligkeiten und Brachydakytlie Typ E wird dieser Phänotyp auch Brachydaktylie-mentales-Retardierungs-Syndrom (BDMR, MIM 600430) genannt. Durch Eingrenzung minimaler krankheitsrelevanter 2q37-Deletionsintervalle wurde das Histondeacetylase-4-Gen (HDAC4, MIM 605314), ein zentraler Transkriptionsrepressor, der in der Gehirn-, Muskel- und Skelettentwicklung involviert ist, als krankheitsrelevantes Gen für das BDMR-Syndrom identifiziert. Bislang wurden intragenische HDAC4-Mutationen bei 2 Patienten mit BDMR-Syndrom nachgewiesen, bei denen zunächst aufgrund von Verhaltensauffälligkeiten klinisch ein Smith-Magenis-Syndrom vermutet worden war. Untersuchungen mittels Array-CGH („comparative genomic hybridization“) decken ein breiteres phänotypisches Spektrum des 2q37-Deletionssyndroms als bislang bekannt auf. So war der Nachweis einer 2q37-Deletion auch bei entwicklungsverzögerten Patienten ohne BDE möglich.
    Medizinische Genetik 03/2012; 24(1). DOI:10.1007/s11825-012-0318-z · 0.09 Impact Factor